Measuring breathing reflex response in heart failure with preserved ejection fraction
Checks how strongly breathing responds to gas levels in people with heart failure.
Plain-language title generated from the registry record
Registry title: Chemoreflex Sensitivity in HFpEF
Key facts
- Where
- Milan, ItalySee the site
Where in Italy
- Ospedale San Luca IRCCS Istituto Auxologico ItalianoMilan, ItalyNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Istituto Auxologico Italiano
- Trial code
- NCT06309537
- Record updated
- 13 March 2024
- Original description
Patients with heart failure and a preserved left ventricular ejection fraction (HFpEF) almost invariably complain of exertional breathlessness. Abnormal cardiac hemodynamics with pulmonary congestion are believed to trigger dyspnea in this patients. However, some patients may complain of exertional breathlessness which seems to be out of proportion as compared with hemodynamic abnormalities.Read full original descriptionShow less
Chemoreflex Sensitivity in Heart Failure With Preserved Ejection Fraction
Patients with heart failure and a preserved left ventricular ejection fraction (HFpEF) almost invariably complain of exertional breathlessness. Abnormal cardiac hemodynamics with pulmonary congestion are believed to trigger dyspnea in this patients. However, some patients may complain of exertional breathlessness which seems to be out of proportion as compared with hemodynamic abnormalities.
Chemoreflex sensitivity accounts for the ventilatory responses to a variety of chemical stimuli, including carbon dioxide produced by the organism during exercise. Chemoreflex sensitivity can be augmented in heart failure with reduced left ventricular ejection fraction, and an increased chemoreflex sensitivity has been linked to symptoms, neurohumoral activation, breathing disturbances, and adverse prognosis.
However, the clinical correlates and implications of chemoreflex sensitivity in HFpEF have not been accurately studied.
We aim to characterize chemoreflex sensitivity in patients with a diagnosis of HFpEF, and to correlate chemoreflex sensitivity with clinical and hemodynamic characteristics.
Inclusion: diagnosis of symptomatic HFpEF (group 1); diagnosis of asymptomatic left ventricular diastolic dysfunction with echocardiographic signs of PH (group 2); healthy volunteers (group 3).
Exclusion: breastfeeding or childbearing.